Revenue in Q3 2024 increased 20%, driven by volume growth from Mounjaro and Zepbound, partially offset by $1.42 billion of revenue in Q3 2023 from the sale of rights for the olanzapine portfolio ...

The global injection pen market is expanding at a fast rate with the growing prevalence of chronic diseases, and increasing demand for convenient self-administration options. This trend is a move ...

Shares of Eli Lilly have gained considerably throughout 2024, thanks in large part to the company's success in diabetes and obesity care. Outside of weight loss, Eli Lilly has a major opportunity ...

A new treatment combining ReCET and semaglutide eliminated insulin use in 86% of type 2 diabetes patients, improving natural insulin sensitivity. A new treatment combining ReCET and semaglutide could ...

“Notably, glucose values vary over a narrow range (from approximately 2 to 20-30 mM [36 mg/dL to 360-540 mg/dL] in people with diabetes), so a rather steep change in insulin bioactivity must be ...

Several types of injections are used to relieve knee pain symptoms, such as steroid injections, hyaluronic acid (HA), platelet-rich plasma (PRP), and regenerative therapies. Knee injections for pain ...

The sharp movement in the early deals was seen after the company announced that it had filed its fast-acting insulin analog, Aspart injection (ASPARAPID), with the Drug Controller General of India.

Yet, Eli Lilly's GLP-1 medications are helping it compete with the leader. Plus, Lilly also has several other promising catalysts to consider. These are two of healthcare's biggest darlings right ...